A Wexford-based biotech firm has appointed a new chief scientific and medical officer to the company's leadership team following the acquisition of rights to an allogeneic immuno-oncology platform and a clinical-stage program.
Coeptis Therapeutics Holdings Inc. announced that Dr. Colleen Delaney assumes the post as a result of a recent agreement Coeptis made with Deverra Therapeutics.
Delaney, who has more than two decades of experience as an oncologist and stem cell transplant physician-scientist, has also served on numerous cell and gene therapy-focused federal advisory committees and as a director at several nonprofit associations.
"Dr. Delaney is a visionary researcher who has dedicated her life to patients as a practicing physician and through her career as a global leader advancing all aspects of cell therapy product development," Dave Mehalick, president and CEO of Coeptis, said in a prepared statement. "Colleen’s work with Deverra and the impressive pipeline of technologies she developed demonstrate her ingenuity and scientific acumen."
Coeptis, a biotech firm working to develop cell therapy platforms for cancer treatments, secured exclusive licensing rights from Deverra to two Investigational New Drug applications and two drug assets that are in Phase 1 clinical stage trials on Aug. 17, making the Pittsburgh firm a clinical stage company.
